BNTX
BioNTech SE
99.29
USD
This page is just a preview of the data found in TrendSpider’s full version
BioNTech SE stock is up 3.66% since 30 days ago. The next earnings date is Mar 25, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 20% of the previous 4 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 3 PUTs, 7 CALLs. 67% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 08 Nov 18:17 | 17 Nov, 2023 | 105.00 | 488 | ||
| 10 Nov 18:30 | 17 Nov, 2023 | 105.00 | 534 | ||
| 15 Nov 15:11 | 17 Nov, 2023 | 105.00 | 434 | ||
| 20 Nov 15:39 | 15 Dec, 2023 | 60.00 | 18 | ||
| 27 Nov 20:18 | 15 Mar, 2024 | 105.00 | 26 | ||
| 30 Nov 16:24 | 15 Dec, 2023 | 100.00 | 665 | ||
| 30 Nov 16:29 | 15 Dec, 2023 | 100.00 | 665 | ||
| 30 Nov 16:38 | 15 Dec, 2023 | 100.00 | 665 | ||
| 30 Nov 16:47 | 15 Dec, 2023 | 100.00 | 665 | ||
| 30 Nov 18:49 | 15 Dec, 2023 | 100.00 | 665 |
BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma. It also develops neoantigen specific immunotherapy, such as Autogene cevumeran (BNT122) and BNT141.
